The Stampede team are pleased to announce that the "transdermal oestradiol comparison" (Arm L) was activated today (20/06/2017) at 9am. We have 40 sites ready to randomise and we will continue to re-open sites as quickly as possible. Congratulations to all sites that were ready on Day 1! If you are yet to receive a green light activation you cannot randomise. To complete the activation process look here. ...
Upfront abiraterone improves survival for men with prostate cancer
Giving the drug abiraterone alongside standard hormone therapy improves the survival of men with high-risk or advanced prostate cancer, according to results from the STAMPEDE trial, published in the New England Journal of Medicine on 3 June 2017. In the “abiraterone comparison” in STAMPEDE, 957 men who were randomised to receive standard of care (hormone therapy with or without radiotherapy) were compared to 960 men who were randomised to receive abiraterone plus prednisolone plus standard of care (hormone therapy with or without radiotherapy). Men in the abiraterone group had four abiraterone tablets and one prednisolone tablet a day. Abiraterone (also known as abiraterone acetate, or Zytiga) is a type of hormone therapy that works in a different way to standard hormone therapy. Abiraterone is currently licensed to treat prostate cancer that has spread and has stopped responding to standard hormone therapy. STAMPEDE tested using it earlier, when men were starting standard hormone th ...
MRC Clinical Trials Unit at UCL
90 High Holborn